[email hidden] (Izabella) wrote in message news:<[email hidden]>...
Quoted message said:Age 28 BLoodwork: fsh 4 lh 1 prolactin 8 estradiol 54 prog. 1.2 free test .6
As the title of my message suggests, this IS a hypothalamic problem.
I was on the pill when I lost my periods, so nobbody did hormone bloodowrk. It was obvious that it
was bodyfat and exercise related (I was 102 pounds, 12% bf)
I think it's silly that they won't *give* someone GnRH pulse unless they want to get pregnant.
That would be nice to have a baby, but the
Quoted message said:-which is needed to conceive.
COMMENT:
You don't need GnRH to raise your testosterone. Why pay thousands of dollars for something that
costs a few dollars?
I have read every endocrinology test and
Quoted message said:study on amenorrhea I can get my hands on, and unfortunately, I likely know more than you do about
this topic. They won't give testosterone repolacement to someone my age.
Maybe just not to someone of your arrogance. Or your lack of forthcoming (since you've yet to GIVE
your age in two messages, and despite a request). If your testosterone levels test low for a woman,
and you have libido problems, you can somewhere find a doctor to give you replacement to
out your phonebook.
Second option is that you can always take DHEA-S, which is OTC. If your T is really low as a female,
this should raise it significantly.
SBH
Menopause. 2003 Sep-Oct;10(5):390-8.
function in premenopausal women.
Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR.
Jean Hailes Foundation Research Unit, Clayton, Victoria, Australia; and the Department of
Epidemiology and Preventive Medicine, Monash University, Central and Eastern Clinical School,
Prahran, Victoria, Australia.
SUMMARY: OBJECTIVE Circulating testosterone in women declines during the late reproductive years
such that otherwise healthy women in their 40s have approximately half the testosterone level as
women in their 20s. Despite this, research showing the benefits of androgen replacement has been
limited to the postmenopausal years. In view of the known premenopausal physiological decline in
testosterone, we have evaluated the efficacy of transdermal testosterone
premenopausal women presenting with low libido.DESIGN Premenopausal women with low libido
participated in a randomized, placebo-controlled, crossover, efficacy study of testosterone cream
(10 mg/day) with two double-blind, 12-week, treatment periods separated by a single-blind, 4-week,
washout period.RESULTS Thirty-four women completed the study per protocol, with 31 women (mean age
39.7 +/- 4.2 years; serum testosterone 1.07 + 0.50 nmol/L) providing complete data. Testosterone
therapy resulted in statistically significant improvements in the composite scores of the
Psychological General Well-Being Index [+12.9 (95% CI, +4.6 to
(95% CI, +6.5 to +25.0), P = 0.001] compared with placebo. A mean decrease in the Beck
Depression Inventory score approached significance [-2.8 (95% CI, -5.7 to +0.1), P = 0.06]. Mean
total testosterone levels during treatment were at the high end of the normal range, and
estradiol was unchanged. No adverse effects were reported.CONCLUSIONS Testosterone therapy
improves well-being, mood,
function in premenopausal women with low libido and low testosterone. As a
well-being during their late reproductive years, further research is warranted to evaluate the
benefits and safety of longer-term intervention.
PMID: 14501599 [PubMed - in process]
Decreased testosterone in regularly menstruating women with decreased libido: a clinical
observation.
Guay AT.
Drive, Peabody, MA 01960, USA.
Much more information is available concerning decreased libido in postmenopausal than in
premenopausal women. Even less is known about androgen deficiency in younger women. We measured
total and free testosterone levels in 12 consecutive premenopausal women complaining of decreased
libido. Of the 12 women, 8 had low or immeasurable levels of testosterone despite having regular
menstrual periods. Androgen precursor hormones, DHEA-S and Androstenedione, were low-normal to high-
normal. Treatment with oral DHEA, 50 to 100 mg per day, restored
desire in 6 of the 8 women, gave partial improvement in one, and failed in another. Possible
significance and etiological mechanism are discussed.
PMID: 11554213 [PubMed - indexed for MEDLINE]
J Reprod Med. 2001 Mar;46(3 Suppl):291-6.
Testosterone deficiency in women.
Davis S.
Jean Hailes Foundation, 173 Carinish Road, Clayton, Victoria, 3168, Australia.
[email hidden]
enhancing
stimulation. Testosterone is also associated with greater well-being and with reduced anxiety and
depression. Clinical and biochemical definitions of T deficiency have not been established; hence,
the prevalence of this condition is not known. However, surgically menopausal women are among the
populations most likely to experience T deficiency, a syndrome characterized by blunted or
diminished motivation; persistent fatigue; decreased sense of personal well-being; sufficient plasma
estrogen levels; and low circulating bioavailable T (either a low
hormone binding globulin (SHBG) ratio or free T in the lower one-third of the female reproductive
range); and low libido. Exogenous estrogen, particularly when administered orally, increases SHBG,
which, in turn, reduces free T and estradiol (E2). After oophorectomy, levels of T and its
precursor, androstenedione, decline by approximately 50%. T replacement continues to be evaluated as
an adjunct to estrogen replacement therapy, particularly for women with androgen deficiency
symptoms, surgically menopausal women and women with premature ovarian failure. In the United
States, oral methyltestosterone is the common product currently approved for androgen replacement in
women. The best product specifically designed for women has yet to be determined, as standardized,
long-term, randomized, control clinical studies are lacking and product refinement continues.
Publication Types: Review Review, Tutorial
PMID: 11304877 [PubMed - indexed for MEDLINE]
Fertil Steril. 2003 Jun;79(6):1341-52.
Comparative effects of oral esterified estrogens with and without
function in
Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG.
Department of Obstetrics and Gynecology, Columbia University, College of Physicians and Surgeons and
New York Presbyterian Hospital, New York, New York 10032, USA. [email hidden]
relative androgen insufficiency after menopause. We sought to characterize the hormonal effects of
the combination of oral esterified estrogens and methyltestosterone
desire. DESIGN: Double-blind randomized trial. SETTING: Healthy volunteers in a multicenter research
environment. PATIENT(S): Postmenopausal women taking
INTERVENTION(S): 4 months of treatment with 0.625 mg of esterified estrogens (n
= 111) or the combination of 0.625 mg of esterified estrogens and 1.25
mg of methyltestosterone (n = 107). MAIN OUTCOME MEASURES: Baseline and end-of-study
hormone-binding
as rated
combination of esterified estrogens and methyltestosterone significantly increased the concentration
of bioavailable testosterone and suppressed SHBG. Scores measuring
baseline with combination treatment and were significantly greater than those achieved with
esterified estrogens alone. Treatment with the combination was well tolerated. CONCLUSION(S):
Increased circulating levels of unbound testosterone and suppression of SHBG provide a plausible
hormonal explanation for the
combination of esterified estrogen and methyltestosterone.
Publication Types: Clinical Trial Multicenter Study Randomized Controlled Trial
PMID: 12798881 [PubMed - indexed for MEDLINE]
